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Health care is often represented as a purely “social” sector, implying that health care 
expenditure is a burden on the economy. We argue in this paper that on the contrary, health 
care is economically productive, and that health care in Tanzania could be much more 
economically and socially productive if health policy and industrial policy were more closely 
integrated. Increasing the depth and breadth of domestic economic linkages between the 
health services and industrial and commercial suppliers within the Tanzanian economy can 
strengthen	economic	development	while	improving	health	care.	The	paper	begins	by	defining	
what we mean in this paper by “health services”, “health care” and “health sector”. It then 
examines	the	economic	size	of	health	care	(production	and	financing),	the	employment	it	
generates, and its linkages to the wider economy through procurement and wholesaling. It 
demonstrates	that	the	health	sector,	broadly	defined,	is	economically	important	as	a	major	
service sector, a location of investment, a generator of employment and income, a sector of 
skilled training and employment, and a location for industrial growth. 
The health of the health sector is very important for the health of the wider economy. The 
rest of the paper analyses the linkages between health care and manufacturing in Tanzania 
in more detail. It traces the declining share of local manufacturers of medicines and other 
health	supplies	 in	 the	expanding	Tanzanian	domestic	market,	quantifies	 the	scale	of	 this	
missed opportunity for industrial development to supply the needs of health care, and 
examines its causes. Finally, the paper looks at the scope for integrating health and industrial 
policy, arguing that reconstruction of these domestic economic linkages is both possible 
and	desirable.	Health	policy	strongly	 influences	 industrial	development.	Furthermore,	 the	
Tanzanian	public	health	services	suffer	severely	 from	shortages	of	essential	supplies.	We	
argue that it is possible for economic and social policy, working together, to strengthen and 
deepen	economic	ties	within	the	economy,	to	the	benefit	of	both	the	effectiveness	of	health	
services and public health, and manufacturing employment and development.
 
ABSTRACT
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This background paper takes as its starting point the framing of the THDR 2017 in the initial 
Concept Note (Kida and Wuyts, 2015) as aiming to develop an understanding of social 
and economic policy as mutually constitutive. We aim to contribute to the development 
of that argument for the case of health. We examine the productive nature of health care 
in Tanzania, identifying interlocking ways in which investment in the health sector, using a 
broad	definition	of	 that	 sector,	 is	economically	and	socially	productive	 for	 the	Tanzanian	
economy	 and	 population.	We	 argue	 that	 the	 so-called	 “social	 sector”	 of	 health	 care	 is	
actually a key economic sector in its own right, contributing to economic development, 
as	well	as	an	important	sector	directly	influencing	human	well-being	through	the	services	
it provides. We build on the overview and historical analysis of the evolution of the sector 
provided in the Background Paper for the THDR 2014 on health sector reforms and health 
services	(Mujinja	and	Kida,	2014),	to	argue	that	the	mutually	constitutive	nature	of	health	
and industrial policy could be strengthened greatly, with considerable economic and social 
benefits	for	the	Tanzanian	population.
1.1  The Productive Impact of Health Care: Health Services, Employment, 
and Industrial Linkages
Health care is often represented as a purely “social” sector, implying that health care 
expenditure is a burden on the economy. We argue in this paper that, on the contrary, health 
care is economically productive, and that health care in Tanzania could be much more 
economically and socially productive if health policy and industrial policy were more closely 
integrated. Increasing the depth and breadth of domestic economic linkages between 
health services and industrial and commercial suppliers within the Tanzanian economy can 
strengthen economic development while improving health care. 
Health	care	delivered	by	public	health	facilities,	by	faith-based	and	private	facilities,	and	by	
private shops plays two distinctive economic roles in the development of the domestic market. 
First, health service employment generates an important element of domestic demand via 
the	multiplier	effect.	This	is	a	macroeconomic	impact.	Health	facilities,	pharmacies,	and	drug	
shops employ large numbers of people (see Section 2). Government expenditure on health is 
largely	spent	on	wages	and	salaries,	and	this	has	an	important	multiplier	effect,	generating	a	
second round of spending on wage goods, much of it within the domestic economy. In the 
faith-based	and	private	sectors,	investment	in	facilities	and	shops	generates	employment	
that	again	has	a	multiplier	effect	on	domestic	demand.	Since	personal	savings	rates	from	
wages	and	salaries	are	quite	low,	the	multiplier	effect	of	government	health	spending	and	
private	and	 faith-based	 investment	on	final	demand	 in	 the	economy	 is	 likely	 to	be	quite	
large.	Health	care	also	attracts	 large	aid	 inflows	 that	also	boost	employment	and	hence	
demand through the same route (see Section 2). 
Second, health care has a sectoral impact that also generates positive macroeconomic 
effects.	Health	care	requires	large	amounts	of	goods	and	services	as	inputs	to	its	production.	
1.  INTRODUCTION: HEALTH, 
PRODUCTION, AND THE ECONOMY
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These inputs include medicines, a wide range of other medical supplies and equipment, 
and many other basic supplies such as packaging and cleaning materials (see Section 3; 
Tibandebage et al., 2016). As a result, the procurement activities of government health care 
providers and the government wholesaler (the Medical Stores Department, MSD), as well 
as purchasing from private wholesalers by all sectors of health care, generate high levels 
of demand for goods and services. The more that this demand is supplied by domestic 
producers,	 the	 more	 the	 demand	 generates	 employment	 in	 the	 non-health	 industrial	
and service sectors. In other words, health service procurement opens up opportunities 
for industrial investment and commercial investment (see Sections 3 and 4), generating 
economic growth. Furthermore, the health sector acts as a locus and stimulator for 
research, innovation, investment, and growth in the wider economy, through its ability to use 
effectively	inputs	of	knowledge,	services	and	supplies;	health	facilities	also	provide	sites	for	
research,	and	for	the	effective	use	of	appropriate	manufacturing	investment	and	innovation.	
Improved purchasing, and closer links to education, training, and research, can increase 
the productive sectoral and macroeconomic impact of health care in the wider economy 
(see	Section	4).	Furthermore,	reducing	the	very	high	import-dependence	of	health	care	–	by	
reducing the ratio of imports to domestic production in supplying health services’ demands 
–	may	also	help	to	tackle	the	national	trade	deficit	in	the	medium	term.
These two economic impacts of health care are very poorly documented and studied in 
the international literature and national policy debates at present. Our aim in this paper is to 
contribute	to	highlighting	the	developmental	opportunities	that	arise	from	health-industrial	
linkages. Inclusive economic development requires the expansion of the domestic market – 
that is, the expansion of local production of goods and services for consumption within the 
country. Only by deepening these internal economic linkages, between the consumption 
of essential goods and services and the employment of people to produce them, can the 
inclusion of the population in economic growth be pursued. Production for export is also 
developmentally essential to reduce the trade gap and bring foreign exchange into the 
economy, but exporting alone cannot sustain inclusive development. We argue here for 
strengthening the domestic linkages between health services and industrial development as 
one important route to improved economic and social development. 
There	is	also	a	third	route	by	which	health	care	influences	economic	and	social	development,	
namely through its direct impact in improving health status. If health care, including public 
health,	is	effective	in	improving	population	health,	then	it	contributes	importantly	to	creating	
a more capable, energetic, skilled, and productive workforce. This is the best documented 
economic impact of health care. It helps to sustain the health and strength of people of 
working age, raising their productivity in work, helping to ensure their energy to develop 
skills and knowledge, to run businesses, hence contributing to productivity and economic 
growth.	Effective	health	care	supports	women	of	child-bearing	age	to	sustain	and	regain	
their	 health	 through	 childbirth,	 helping	 to	 ensure	 healthy	 children	who	 can	 benefit	 from	
education; it also increases longevity and helps to maintain people through economically 
and socially active older ages. Conversely, therefore, bad health care that lowers population 
health undermines the productivity of the economy as a whole. 
Econometric	 work	 confirms	 this	 impact	 of	 improvements	 in	 health	 status	 on	 economic	
growth	and	productivity,	especially	at	low	income	levels	(López-Casasnovas	et	al.,	2005).	In	
African contexts researchers have found a positive association between health expenditure 
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and	population	health	(with	public	health	expenditure	effects	being	stronger	than	private),	
and	 between	 population	 health	 and	 labour	 force	 participation	 (Anyanwu	 and	Erhijakpor,	
2007;	 Novignon	 et	 al.,	 2012,	 2015).	 There	 are	 also	 cumulative	 feedback	 effects,	 since	
socio-economic	 status	 is	 found	 to	 have	 a	 causal	 effect	 on	 health	 status	 (Ajakaiye	 and	
Mwabu, 2012, using Kenyan data). Conversely, maternal mortality, which remains high 
across	much	of	Africa,	has	major	negative	effects	on	non-health	GDP	(Kirigia	et	al.,	2014).	
We do not survey this substantial literature further here, nor discuss in any more depth this 
well	documented	impact,	noting	only	that	it	underscores	the	productive	effects	of	improved	
health	status	through	increases	in	effective	health	care	expenditure.
1.2 Sources and Methods
This	paper	draws	mainly	on	a	DFID-ESRC	funded	research	project	hosted	in	2012–15	by	
REPOA in Tanzania. Entitled Industrial productivity, health sector performance, and policy 
synergies for inclusive growth: A study in Tanzania and Kenya, the hypothesis addressed 
by	the	research	project	was	that	there	are	unexploited	synergies	between	upgraded	local	
industrial supply of pharmaceuticals, equipment, and other essential medical supplies, and 
the improvement of health services’ quality and inclusiveness; and that there is scope for 
effective	policy	intervention.	The	research	in	Tanzania	included	a	quantitative	and	qualitative	
study	of	the	supply	chains	into	health	care,	in	public,	faith-based	and	private	facilities	and	
shops (Tibandebage et al., 2014). In total, those responsible for procurement were interviewed 
in	 42	 facilities	 and	 shops	 in	 four	 districts	 in	 two	 regions	 of	 Tanzania.	 Semi-structured	
interviews on procurement experience, practices, and challenges were supplemented in 
each facility or shop with data on the availability of a set of “tracer” essential medicines and 
other essential supplies (see list in Appendix to this paper). All interviewees were asked 
about the balance of locally produced vs. imports in their supply chain, and their opinions 
on locally manufactured supplies. 
In	a	second	round	of	research,	all	active	pharmaceutical	firms	in	Tanzania	were	interviewed	
about	 their	 experience	 of	 supplying	 the	 Tanzanian	 health	 sector;	 in	 addition,	 six	 firms	
supplying	 non-pharmaceuticals	 were	 also	 interviewed,	 including	 suppliers	 of	 bed	 nets,	
mattresses, cleaning equipment, and plastic packaging. Finally, wholesalers and policy 
makers	were	also	interviewed.	High-level	policy	dialogues	in	Tanzania	reviewed	the	findings	
and fed into recommendations.
In	addition	to	findings	from	this	project,	this	THDR	background	paper	is	based	on	document	
searches concerning health sector funding in Tanzania, a literature review on the economic 
effects	of	health	care	investment,	and	the	collection	of	health	sector	and	relevant	industrial	
data.	Tables	and	figures	are	from	the	authors’	primary	research	except	where	indicated.	
1.3 Organization of the Paper
Section	2,	“The	Economic	Importance	of	the	Health	Sector”,	defines	what	we	mean	in	this	
paper by “health services”, “health care” and “health sector”. It then outlines the economic 
size	of	health	care	(production	and	financing),	the	employment	it	generates,	and	its	linkages	
to the wider economy through procurement and wholesaling. It demonstrates that the health 
sector,	 broadly	 defined,	 is	 economically	 important	 as	 a	major	 service	 sector,	 a	 location	
of investment, a generator of employment and income, a sector of skilled training and 
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employment, and a location for industrial growth. The health of the health sector is very 
important for the health of the wider economy.
Section 3, “Linkages between Health care and Manufacturing”, examines in more detail the 
impact of health care on manufacturing in Tanzania. It traces the declining share of local 
manufacturers of medicines and other health supplies in the expanding Tanzanian domestic 
market,	quantifies	the	scale	of	this	missed	opportunity	for	industrial	development	to	supply	
the needs of health care, and examines its causes. 
Finally, Section 4, “Integrating Health and Industrial Policy”, argues that reconstruction of 
these domestic economic linkages is both possible and desirable. Health policy operates, 
necessarily,	 as	 ‘implicit’	 industrial	 policy,	 strongly	 influencing	 industrial	 development.	
Furthermore,	the	Tanzanian	public	health	services	suffer	severely	from	shortages	of	essential	
supplies.	Given	these	findings,	we	argue	that	it	is	possible	for	economic	and	social	policy,	
working together, to strengthen and deepen economic ties within the economy, to the 
benefit	of	both	the	effectiveness	of	health	services	and	public	health,	and	manufacturing	
employment and development.
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By “health services” we mean the care provided to the population by health facilities 
(public,	 faith-based,	 and	 private).	 By	 “health	 care”	we	mean	 those	 health	 services	plus 
retail medicines sales in pharmacies and shops. By “health sector” we mean health care 
plus public health activities (such as surveillance and prevention), industrial and commercial 
supply	 of	 inputs	 to	 health	 service	 providers	 (and	 those	 firms’	 inputs	 in	 turn),	 the	 higher	
education	and	training	institutions	for	health-related	skills	and	knowledge,	and	the	scientific,	
technical, and regulatory institutions that support health care quality and improvement. In 
itself	that	list	makes	clear	the	importance	of	the	sector.	(Yet	even	this	extensive	list	does	not	
include	many	health-related	activities	in	the	economy,	from	traditional	healers	to	providers	of	
clean water and sanitation and changes in quality and availability of food. We do not discuss 
those latter activities further here.)
Measuring and describing the economic importance of the health sector in that broad sense 
is	difficult	because	of	data	 limitations;	estimates	of	 its	size	are	generally	underestimates.	
This	section	argues	that	health	care,	as	measured	by	financial	flows,	is	a	large,	productive	
element	of	the	economy	(see	Section	2.1),	that	 it	employs	 large	numbers	of	skilled	staff,	
including those in industrial supply sectors and medicines distribution (see Section 2.2), and 
that its linkages to industrial and commercial suppliers generate an important developmental 
impact	in	the	wider	economy.	Each	section	identifies	areas	where	the	productive	impact	of	
health care in the economy could be enhanced, with particular emphasis on strengthening 
the linkages between health care and the wider economy. 
2.1	 Production	and	financing	of	health	care
How economically important is health care? A standard indicator from the Tanzanian national 
accounts is the share of health services’ value added in GDP. However, this provides a 
misleadingly small estimate: Table 1 shows that, measured by value added, the Tanzanian 
economy has a large services sector, but less than 2% of GDP is provided by health services.
This low share of value added arises in part from the productive structure of health care, and 
in	part	from	industrial	classifications.	As	outlined	below,	health	facilities	are	predominantly	
public	and	non-profit,	while	private	 facilities	 frequently	 report	 low	or	no	profits,	so	health	
facilities’ value added consists mainly of labour costs. Furthermore, the large public 
administration category (10.61% of GDP in 2012) will include health sector administration, 
just	as	education	will	include	training	for	the	health	sector,	and	trade	will	include	pharmacies,	
all therefore not included in Table 1, columns 2 and 5. 
2.  THE ECONOMIC IMPORTANCE OF 
 THE HEALTH SECTOR
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Table 1: Tanzanian health services and all services: Sectoral value added as
% GDP at market prices (2004, 2008, 2012)
Health 
services* 
value added 
(TZS millions)
All services 
value 
added (TZS 
millions)
GDP Current 
market 
prices (TZS 
millions)
Health 
services* 
share of 
GDP (%)
All 
services 
share of 
GDP (%)
2004 200,933 5,870,447 13,971,592 1.44 42.02
2008 210,525 7,085,136 14,828,345 1.42 47.78
2012 737,964 19,618,090 44,717,663 1.65 43.87
Source: Ministry of Finance (2012), Table 3, p. 13.
*“Health services” in this table does not appear to include retail pharmacies and shops 
selling medicines; they are likely to be included in the Trade services category.
By measuring only value added in health services, Table 1 therefore sharply underestimates 
the importance of health care in the national economy. As Table 2 shows, measures 
of	health	care	financing	 indicate	that	health	care	makes	up	a	substantially	higher	share	
of national economic activity. The National Health Accounts (NHA) give Tanzania’s most 
complete assessment of health spending in the economy; the draft NHA for 2011/12 
estimates health spending at 8.3% of the national economy (see Table 2, row 1): this is 
a	substantial	share	of	all	economic	activity	in	Tanzania.	Alternative	figures	for	the	ratio	of	
total health spending to national income vary according to the methodology used between 
5.8% and 7.1% (Table 2, rows 2 and 3). Furthermore, health spending by households was 
estimated	at	3.1%	of	consumption	spending	and	7%	of	non-food	spending	in	2011/12	
(see Table 2, rows 4 and 5). 
However, there are many constraints on the productive use of Tanzanian health care 
financing.	 Financing	 is	 fragmented,	 and	 is	 dominated	 by	 non-government	 (donor	 and	
private household) spending. By contrast, the provision of health services is dominated by 
public	and	non-profit	(mainly	faith-based)	providers.	This	creates	a	complex	and	financially	
constrained health care system, undermining access and quality of care. 
The	National	Health	Accounts	show	that	health	care	is	financed	from	three	major	sources:	
government funds; donor funds (some of which go to the government budget while 
some	are	spent	directly	–	see	below);	and	private	spending	which	is	largely	spent	out-of-
pocket	by	households	on	a	fee-for-service	basis	and	for	medicines,	with	a	small	insurance	
contribution	(see	Table	3,	row	4).	The	major	shift	in	spending	shares	over	the	last	decade	
(see	Table	3)	was	from	public	to	donor	financing:	by	2011/12,	donors	were	funding	nearly	
half of health care spending (see Table 3, row 2), a share that looks unsustainable. The 
shares	fluctuate	over	time,	but	the	dominance	of	non-government	funding	persists:	WHO	
data for 2013 indicate 33.2% of health funding from external sources, and 36.3% private, 
mainly	out-of-pocket	spending.1 Furthermore, according to the most recent NHA data, 
the public sector spent 38.4% of total health funding in 2011/12, while raising only 20.7% 
from public funds. This implies limited government leverage over the use of public health 
expenditure.
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Table 2: Financing indicators for the size of Tanzanian health care
relative to the national economy, various years 
Indicator and units Year Health National or total
Health 
%
1 Total health spending /nominal GDP (TZS million/year) (NHA) 2011/12 3,127,221 37,532,962 8.3
2 Total health spending /GNI (US$/head PPP basis) (WHO) 2012 117 1650 7.1
3 Total health spending/GNI (US$/head exchange rate method) (WHO/World Bank) 2013 49 850 5.8
4
Mean household health spending/mean 
household consumption expenditure (TZS/
month) (Tanzania mainland)
2011/12 8,021 258,751 3.1
5
Mean household health spending/
mean	non-food	household	consumption	
expenditure (TZS/month) (Tanzania 
mainland)
2011/12 8,021 115,239 7.0
Sources: 
1.  Tanzania National Health Accounts (NHA) data for 2011/12; data obtained from the 
Department of Policy and Planning, Ministry of Health, Community Development, Gender, 
the Elderly, and Children (MHCDGEC).
2. World Health Organization, http://apps.who.int/gho/data/node.country.country-TZA.
3.  World Health Organization, http://apps.who.int/gho/data/node.country.country-
TZA, accessed 04.03.16; World Bank, http://databank.worldbank.org/data/reports.
aspx?source=2&country=TZA&series=&period=, accessed 04.03.16.
4. NBS (2014).
5. NBS (2014).
The Tanzanian health facilities on which the population relies, however, are mainly owned and 
run	by	government	or	faith-based	organizations	(FBOs),	though	the	private	sector	has	been	
expanding	since	 the	early	1990s	when	 for-profit	private	practice	was	 re-introduced	after	
being banned in 1977. The rural areas continue to be served mainly by public health facilities. 
The public sector has, in principle, a pyramidal structure with referral from dispensaries at 
the lowest level to zonal specialized consultant and national hospitals, though patients often 
go straight to higher levels for serious illnesses. Table 4 shows the current distribution of 
health facilities in Tanzania mainland by level and ownership of health facility.
Some	 faith-based	 hospitals	 operate	 as	District	 Designated	Hospitals,	with	 salaried	 staff	
supported by government funds. The dominance of the public and FBO sectors is greater 
than Table 4 suggests, and is better indicated by the high share of total beds found in these 
two	sub-sectors	(see	Table	5).	The	private	hospitals	are	generally	small.	Furthermore,	the	
last Tanzanian Demographic and Health Survey (2010) estimated that of women delivering 
in health facilities, 97% went to public or FBO facilities (NBS, 2011), and of children with 
diarrhoea taken for treatment of some kind, 22% went to shops and pharmacies and most 
of the rest to public facilities.2 Meanwhile the private sector has tended to bifurcate into two 
sub-sectors:	 low	level	 (often	 low	quality)	 facilities	that	serve	very	 low	income	populations	
such as high density urban areas that have few public dispensaries, and small higher quality 
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facilities serving the small percentage of the population with some form of insurance and 
somewhat higher income levels (Kida, 2009).
Table	3:	Percentages	of	financing	source	for	health	care	
(total health expenditure), 2002/3, 2005/6, 2009/10, 2011/12
Financing source 2002/03 2005/06 2009/10 2011/12
Households 25.4 28.0 26.0 24.7
Donors 27.4 44.0 39.6 48.3
Ministry of Finance 42.0 25.0 32.3 20.7
Other private 5.1 3.0 2.1 6.3
Total 100 100 100 100
Source: MoHSW (2011), National Health Accounts (2002/3–2009/10); 
draft NHA tables (2011/12).3
*Data for 2002/3 - 2009/10 as published in 2009/10 NHA.
Table 4: Distribution of health facilities by level and ownership
(number of facilities) 2015
Level Ownership Private Total
Government FBOs Parastatal
Dispensary 4,502 626 116 716 5,960
Health 
Centre 484 141 12 79 716
Hospital 129 79 15 34 257
Total 5,115 846 143 829 6,933
Source: Desk officer, MoHSW; data as of July 2015.
Table 5: Distribution of available health facility beds by level and ownership 2011
Level
Ownership
Private Total
Government FBOs Parastatal
Health 
Centre 8,766 5,286 271 800 15,123
Hospital 15,697 14,677 800 1,187 32,361
Total beds 24,463 19,963 1,071 1,987 47,484
% of total 51.5 42.0 2.3 4.2 100
Source: MoHSW (2012a).
Given	the	importance	of	the	public	sector,	public	financing	constraint	is	particularly	important	
for health care availability and quality. Ministry of Health data show that public spending on 
health care via the government budget (including donor support) actually fell in real terms 
from 2009/10 to 2011/12 (see Table 6); the fall is particularly sharp in dollar terms (see 
Table 6, row 5), a matter of particular concern given the reliance of the sector on imported 
inputs	(see	further	below).	In	2010/11	and	2011/12	the	under-spend	(“actual”	relative	to	the	
budget) was also large (see Table 6). In 2011/12 the actual public spending on health was 
2.56% of GDP, down from over 3% in 2009/10; in real terms (2001 prices) it fell to UD$6.9 
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per head, down from US$9.55 in 2009/10 (see Table 6, row 5). 
In 2012/13 nominal spending per head fell again, and although it rose in 2013/14 it fell 
back almost to 2011/12 levels in 2014/15,4 implying a continuing and worsening squeeze 
on underfunded public health services as the population rose. Furthermore, at 8.6% in 
2014/15,5 the share of health care in total government spending is far below the 15% 
recommended	in	the	Abuja	Declaration.	The	government	has	also	persistently	underspent	
its	health	budget	(including	donor	support):	the	PER	(MoHSW,	2012b)	notes	difficulties	in	
expending allocated donor funds, because “cumbersome procurement procedures” delay 
expenditure (p.17).
Table 6: Public health spending in nominal and real terms, 2008/9–2012/13
Indicator 2008/9 2009/10 2010/11 2011/12 2012/13
Budget Actual Budget Actual Budget Actual Budget Actual Budget
Nominal 
(TZS billion) 734 707 925 918 1,220 920 1,209 1,051 1,289
Nominal per 
head (TZS) 18,460 17,781 22,655 22,483 29,098 21,943 28,075 24,409 29,150
Real
(TZS billion) 424 408 496 493 605 456 545 474 520
Real per 
head (TZS) 10,651 10,259 12,160 12,068 14,431 10,883 12,653 11,001 11,769
Real per 
head (US$) 8.86 8.54 9.62 9.55 10.90 8.22 7.94 6.90 7.38
Exchange 
rate 1,202 1,264 1,324 1,594 1,594
Deflator
(2001 prices) 1.73 1.86 2.02 2.22 2.48
Source: MoHSW (2014b).
Of this public spending, around two thirds is funded by the government of Tanzania, and 
around a third by donors (see Table 7, rows 1 and 2). Of the donor spending, rather less half 
goes into a “basket” fund that health facilities can draw upon at District and Regional level 
for	medicines	and	other	expenses;	the	rest	is	on-budget,	donor	supported	public	spending	
which	does	not	go	 through	 the	basket	 (see	Table	7).	 There	 is	 also	a	 small	 “off	budget”	
contribution to public health spending (see Table 7, row 5) which consists of user fees and 
charges (“cost sharing”) and spending by the Community Health Funds.6
Table 7: Percentages of public health funding (actuals) by source and year
Source of funding 2008/9 2009/10 2010/11 2011/12
Government of Tanzania 65.3 63.0 61.9 66.9
Foreign 33.9 35.8 36.6 32.1
Of which: Basket 12.1 14.0 13.6 14.2
Non-basket 21.8 21.8 23.0 17.9
Off-budget 0.8 1.2 1.5 1.0
Total 100.0 100.0 100.0 100.0
Source: MoHSW (2014b). 
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The small element of public health spending arising from cost sharing is consolidated in the 
Health Service Fund (HSF). User fees in the public sector were introduced in 1991 after the 
government realized that it was no longer able to provide free essential health care services 
of acceptable quality to all Tanzanians. It was thus expected that user fees would generate 
additional revenues to improve the availability of quality health services. The introduction of 
user fees proceeded in phases, starting with the referral, regional, and district hospitals in 
1993/94. By 2004 user fees had been rolled out to the primary level of health care provision 
–	health	centres	and	dispensaries.	Contribution	of	this	cost-sharing	money	to	the	budget	
in	LGAs	remains	significantly	low:	receipts	were	below	TZS10	billion	in	2011/12	(MoHSW,	
2014b), but the funds are nevertheless an important source of operating expenses for public 
health	facilities	that	otherwise	lack	any	access	to	cash	for	day-to-day	items.	
The	 other	 source	 of	 off-budget	 expenditure	 included	 in	 public	 health	 spending,	 the	
Community Health Fund (CIF) and its urban version Tiba kwa Kadi (TIKA), had very low 
coverage in 2011/12, at 641,753 and 5,951 households respectively (MoHSW, 2014b). 
Assuming membership of six people per household, population coverage was then less 
than	 four	million.	Recent	figures	show	rising	enrolment	 to	over	1.1	million	households in 
2014/15, representing over 14% of the population, with widely varying regional coverage.7 
There is room, therefore, for this complementary source of funding to increase enrolment, 
generate	much	more	revenue,	and	enhance	the	capacity	of	 lower-level	health	facilities	to	
improve the quality of health services while catering for a larger population.
Finally, the National Health Insurance Fund (NHIF) is a social insurance fund taking 
contributions as a share of wages and salaries from employers and employees; it constitutes 
the	largest	source	of	insurance-based	health	expenditure.	Data	on	NHIF	reimbursements	to	
health	facilities	in	2011/12	showed	a	large	majority	of	expenditure	at	hospital	level:	50%	of	
all	spending	went	to	referral	hospitals,	with	just	7%	each	to	dispensaries	and	health	centres.	
By	ownership,	45%	went	to	faith-based	facilities,	29%	to	government,	and	26%	to	private	
facilities (MoHSW, 2014b). The rough equivalence in reimbursements between government 
and private sector is worth noting, given a disproportionately larger number of government 
health	 facilities.	 The	 fragmented	 financing	 system	 creates	 a	 problematic	 public/private	
interface,	and	undermines	value	 for	money	 from	each	financing	stream	 (Tibandebage	et	
al.,	2013).	The	government’s	medium-term	aim	in	health	financing	is	to	move	to	full	national	
health insurance coverage with subsidy for those unable to contribute.8
Most	 private	 and	 donor	 health	 financing	 spending	 is	 thus	 not	 included	 in	 Table	 7’s	 “off	
budget” category. Private funding consists mainly of private purchase of medicines in shops 
and	pharmacies;	donor	funding	goes	to	vertical	programmes	and	NGO	projects;	and	private	
fees	go	to	faith-based	and	private	facilities.	The	government	has	recognized	that	retail	shops	
and pharmacies are an important source of medicines for the population, and require better 
regulation. It has invested heavily with donor support in developing a regulated network of 
drug shops, called Accredited Drug Distribution Outlets (ADDOs). There are currently 7,697 
ADDOs in Tanzania, eclipsing in numbers the 1099 regular pharmacies of which over half 
are in Dar es Salaam.9
All	 sub-sectors	 of	 Tanzanian	 health	 care	 are	 thus	 severely	 cash-strapped.	 The	 financial	
constraints	on	health	services	and	retail	medicine	sales	reflect	low	incomes	and	generalized	
poverty, and undermine their core role of ensuring a healthy and productive population. 
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The	financing	constraint	on	public	health	services	outlined	above	is	particularly	damaging	
in this regard, and reduce the employment and industrial linkages traced in the next two 
sub-sections.	
2.2 The Health Sector as an Employer
The health sector as a whole – health care and its wider linkages in the economy – is 
a	major	 employer,	 notably	 providing	 valuable	 skilled	 employment	 in	 a	 generally	 low-skill	
economy.	Employment	in	health	services	was	registered	at	just	below	5%	of	total	regular	
employment in the economy in 2013 (see Table 8, row 1). Of the approximately 70,000 
regular health services employees, 78% were working in the public sector, 20% in the 
faith-based	sector,	and	 just	2%	 in	 the	private	sector,	emphasising	again	 the	dominance	
of	the	public	and	faith-based	providers	of	health	services	(MoHSW,	2014a).	Furthermore,	
66% were women; the health services are an important employer of skilled female labour. 
Row 2 in Table 8 adds regular employment in the pharmaceutical industries. Since many 
people	seek	first-line	health	advice	and	medicines	in	shops	and	pharmacies,	an	estimate	of	
that additional employment, added in row 3, takes the health sector workforce over 5% of 
regular employment.
Table 8: Health sector employment as a share of total regular employment 2013
Indicator and units Year Health National or total
Health 
%
1 Health service employees/total regular employment (MoHSW/NBS) 2013 70,244 1,547,337 4.5
2
Health service plus pharmaceutical 
production employees/total regular 
employment (MoHSW/NBS)
2013 71,540 1,547,337 4.6
3
Health service plus pharmaceutical 
production employees plus ADDO and 
pharmacy employees (estimate)/total regular 
employment
2013 81,435 1,547,337 5.3
1. Ministry of Finance (2012), p. 94; MoHSW (2014a); NBS (2013a).
2.  As 1, plus National Bureau of Statistics (Annual Survey of Industrial Production) Statistical 
Abstract, (NBS, 2013b). 
3.  As 2, plus Pharmacy Council of Tanzania, data extracted from files (estimated employment: 
1 per ADDO plus 2 per pharmacy).
Investments	in	health	care	and	training,	by	both	the	government	and	the	non-government	
sectors, are potentially expanding employment in the health sector. The government’s 
Primary Health Services Development Programme (MoHSW, 2007) aims to expand sharply 
the capacity of the public health sector, by providing every village with a dispensary, every 
ward with a health centre, and every district with a district hospital. This facility investment 
programme	will	be	productive	only	if	the	current	constraints	on	health	service	staffing	can	
be	broken.	At	present	there	is	severe	understaffing,	putting	the	efficiency	and	efficacy	of	the	
health sector investment at increasing risk, with huge shortages registered across almost all 
professional categories in the public sector. The Human Resources for Health deployment 
tracking study, in 103 districts in 2009, found an overall HRH gap in these districts was 
about 54% (Sikika, 2010). NHA data at that date found a more or less stagnant trend in the 
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number	of	clinical	staff	(physicians,	Assistant	Medical	Officers,	nurses,	and	nurse-midwives)	
(MoHSW,	2011).	The	recorded	number	of	health	workers	in	the	2012	HRH	profile	(64,449)	
was	only	52%	of	requirements	using	the	1999	staffing	norms,	or	36%	of	the	need	using	the	
new	staffing	norms	(MoHSW,	2013).
The latest data (MoHSW, 2014a) show these shortages in stark terms compared to the 
numbers required to provide quality health services to the Tanzanian population. For example, 
at the dispensary level only 4,121 enrolled nurses were available compared to the required 
11,826, and only 408 Assistant Health Laboratory Technologists were available compared 
to the required 5,913. At the health centre level, examples of huge shortages include those 
for enrolled nurses (2,267 available compared to the required 6,399), Medical Assistants 
(2,820 available compared to the required 4,977), and Health Laboratory Technologists 
(132 available compared to the required 711). At the dispensary level, total workforce 
available	(including	support	staff)	was	15,620	compared	to	the	required	workforce	of	53,217	
(MoHSW, 2014a). This was less than one third of the required workforce. 
This	HRH	crisis	has	deep	 roots,	but	was	exacerbated	by	a	government-imposed	public	
sector employment freeze from 1993 to 1999 as part of the measures to address the 
financial	crisis	in	the	public	sector,	and	the	retrenchment	exercise	as	part	of	the	civil	service	
reforms. Between 1994/95 and 2001/02 the number of public sector health workers fell 
from 67,000 to 49,900 (MoH, 2004). Cumulative causes of continuing crisis have included 
some health workers opting to work outside the health sector both locally and abroad. 
For example, while numbers of pharmacists graduating have increased, pharmacists/
pharmacy technicians per 10,000 population fell from 0.15 in 2008 to 0.13 in 2012. These 
inconsistent trends are attributed to employment in private pharmacies (MoHSW, 2013). 
Table 9 documents the persistence of a gap between demand and supply of trained health 
workers	in	the	public	sector.	The	non-public	sector	also	suffers	from	shortages	of	trained	
personnel (MoHSW, 2014a, pp. 38, 39).
Table 9: Percent of recruited public sector health workers against permitted 
posts 2009/10–2013/14
Year New positions granted by PO-PSM
Number of graduates posted 
by MoHSW %
2009/10 6,257 4,090 65
2010/11 7,471 5,704 76
2011/12 9,391 6,704 68
2012/13 8,002 5,702 67
2013/14 11,221 7,677 68
Source: MoHSW (2014a).
Paradoxically, however, these acute shortages sit alongside unemployment among 
graduates	 of	 some	 health-related	 training	 courses,	 including	medical	 doctors	 (MoHSW,	
2014a). Both government and the private sector are investing in training institutions (Table 
10).	By	2014,	private	training	institutions	(FBO	and	for-profit)	accounted	for	46.4%	of	the	
total, including medical and other related sciences up to degree level, including Doctor of 
Medicine,	Clinical	Officer,	Clinical	Assistant,	pharmacy,	nursing	and	midwifery,	paramedical,	
laboratory, and health medical records training. By 2011, of the eight medical schools 
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only	 two	were	 government-run,	with	 the	 remaining	 owned	by	 FBOs	 (four)	 and	 for-profit	
training	 institutions	 (two)	 (MoHSW,	2013).	The	MoHSW	 is	 responsible	 for	all	non-degree	
level	programmes	that	offer	mid-level	cadre	programmes	for	health	professionals.	In	2014	
there	were	a	total	of	82	government-owned	training	institutions	under	the	Ministry	of	Health	
(MoHSW, 2014b). The Ministry is also entrusted with the task of supervising health training 
institutions in the private sector. Furthermore, the government sponsors students pursuing 
higher-level	health-related	training	in	universities,	both	public	and	private.	In-service	training	
including	Continuing	Professional	Development	(CPD)	is	also	provided	for	different	cadres	
to enable them to keep up with new demands on skills.
Table 10: Number of training institutions by ownership: 2007–2014
Ownership Number of Training Institutions2007 2009 2014
Government 62 82 82
FBO 61 49 54
Private 3 3 17
Total 126 134 153
Source: MoHSW (2014b). 
There are a number of interlocking reasons for these shortages alongside unemployment. 
They	 include	 fiscal	 constraints,	 poor	 fiscal	management,	 human	 resource	management	
failings in the sector, poor wages and working conditions that discourage career 
commitment,	and	options	for	migration	and	for	non-health	sector	employment	of	graduates.	
With a population of about 45 million people, the health sector needs to employ more 
skilled	health	workers	to	cope	effectively	with	the	high	burden	of	disease	and	to	support	a	
more capable and productive national workforce. Increased employment will improve health 
services	productivity,	and	create	multiplier	effects	in	the	economy	as	employed	staff	spend	
wages	and	salaries.	For	example,	health	workers’	salaries	account	for	over	60%	of	LGA-
level public health spending (MoHSW, 2014a), and these workers spend their salaries and 
other	monetary	benefits	on	goods,	other	services,	and	even	small	business	 investments	
that generate further economic growth.
2.3 Buying Medicines and Supplies
Health	care,	in	addition	to	providing	essential	services	for	the	population’s	well-being	and	
creating	employment	and	multiplier	effects	on	demand	in	the	national	economy,	has	one	
other	major	economic	impact	in	the	national	economy:	through	the	purchase	of	inputs.	Like	
the	economic	benefits	 from	health	services,	and	health	care	employment	and	 its	 impact	
on	domestic	demand	in	the	economy,	the	procurement	of	inputs	also	has	major	economic	
benefits	which	could	be	still	larger	and	more	productive	if	better	managed.
Health care thus provides an important market for manufacturers of medicines and supplies 
that address some of the population’s basic needs. These medicines and other supplies 
are essential inputs for the provision of quality health services. The availability of essential 
supplies	within	 the	 public	 sector	 fluctuates,	 but	 there	 are	many	 gaps,	 obliging	 patients	
to struggle to buy medicines in shops and pharmacies at higher prices. The Industrial 
Productivity and Health Sector Performance	 research	project	 (see	Section	1)	 undertook	
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exploratory interviews about supply chain experiences that support other evidence in this 
regard. Shortages of supplies were particularly notable in this study in lower level public 
facilities (health centres and dispensaries) visited during the survey in 2012/13. Tables 11 
and 12 show the data for the availability of the set of tracer essential medicines and a set of 
essential supplies including basic equipment and medical supplies, cleaning materials, and 
basic laboratory items (see Appendix for the list of tracer items). Availability was consistently 
better	in	the	faith-based	facilities.
The items ‘never ordered’ by more than 50% of lower level public sector facilities included 
most of the medicines used to treat chronic conditions and mental illness: atenolol 
(hypertension), omeprazole (ulcers), amitriptyline (depression), metformin (diabetes), and 
glibenclamide	(diabetes).	Furthermore,	one	of	our	tracer	medicines	was	injectable	oxytocin,	
used	 for	 treating	 post-partum	 bleeding:	 38%	 of	 lower	 level	 facilities	were	 either	waiting	
for supplies or did not stock it (spread across all sectors). Medical supplies, equipment, 
and other basic supplies also showed relatively low availability in both public and private 
dispensaries and health centres (see Table 12), despite the essential nature of these items. 
The supplies and equipment ‘never ordered’ did not appear to be unnecessary. Nearly 
half of public health centres had no glucometer to test blood sugar for diabetes, and a 
majority	had	never	had	glucometer	strips	 to	use	with	 it;	one	had	never	had	microscope	
slides required for e.g. malaria tests; nearly half had no sharps box; a quarter had never 
had	bed	nets	(though	all	health	centres	have	beds);	a	majority	had	never	ordered	hydrogen	
peroxide for wound cleaning; and one had never had a weighing scale for paediatrics. A 
majority	of	public	dispensaries	lacked	a	microscope	–	and	even	more	lacked	the	slides	for	
it – and while all the public facilities had surgical gloves when visited, we know from other 
evidence	 (Tibandebage	et	al.,	2015)	as	well	as	 interviews	 for	 this	project	 that	protective	
gloves are periodically out of stock.
Table 11: Availability of tracer medicines in lower level facilities, 
y sector (% of all tracers)
Facility/shop sector Availability TotalAvailable On order Never ordered
Public 58 9 32 100
Faith-based 72 7 22 100
Private 63 6 31 100
Total 62 8 26 100
n=624 
Source: project data; Tibandebage et al. (2014).
Table 12: Availability of tracer supplies in lower level facilities, by sector 
(% of all tracers)
Facility/shop sector
Availability
TotalAvailable On order Never ordered
Not 
functioning
Public 62 5 32 1 100
Faith-based 79 3 17 1 100
Private 64 3 33 0 100
Total 66 4 29 1 100
n=781
Source: project data; Tibandebage et al. (2014).
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Interviews	 with	 staff	 members	 in	 health	 facilities	 who	 ordered	 and	 managed	 supplies	
confirmed	problems	and	gaps	in	availability,	including	lengthy	supply	chains,	especially	in	
public dispensaries and all health facilities in the more remote districts; long delays from 
order to delivery; and incomplete supply of orders. Here are a few representative examples 
of respondents’ problems:
Box 1
Medicines from [the public wholesaler] do not come on time. For example, at our centre 
the batch that was to be delivered in December 2012 was delivered on 1 February 
2013. There was no medicine at this centre the whole of January. We wrote to DMO and 
we	were	told	there	was	no	stock.	(In-charge,	public	dispensary,	District	3)
[The public wholesaler] delays delivery of supplies. So it’s so challenging, because we 
are dealing with human beings whose lives we need to save. We don’t have much choice 
other than waiting for [the public wholesaler] to deliver supplies. (Hospital pharmacist, 
public hospital, District 1)
Sometimes up to 45% of the order is reported missing... [The public wholesaler] writes 
‘out of stock’ on so many items on the sales invoice. For example, on 13 January 2013 
the batch from [the public wholesaler] which was ordered in October 2012 had 107 
items but 57 were missing... (Hospital pharmacist, public hospital, District 3)
Persistent supply shortages – and the resultant shift to purchase in shops – thus badly 
undermine the productivity of the public health services. Nurses and doctors cannot provide 
good quality care without reliable access to essential medicines and supplies. Health 
service	medicines	and	supplies	rely	very	heavily	on	the	two	main	non-government	sources	
of funding: donors and private OOP payment. Donors have greatly increased their funding 
for medicines and supplies in recent years, notably for HIV/AIDS, TB and malaria medicines, 
and subsidized bed nets. Data on the size and funding of the medicines market as a whole 
are poor, but it is clear that the Tanzanian government now relies heavily on this donor 
funding, using domestic health public expenditure for salaries and other items instead (see 
Table 13). While the estimates in Table 13 have a margin of error, and while the percentages 
vary substantially from year to year, the implication that the Tanzanian government currently 
has little funding leverage over health sector supplies seems to be robust. There have been 
some negative consequences of this loss of policy leverage for the wider impact of the 
health services on the Tanzanian economy as a whole, discussed in Section 3. 
Table 13: Estimate of the approximate share of domestic public expenditure 
in the domestic medicines market (year to which data refer in brackets)
US$ millions % of total market
Estimate of total market size* 250 100% (2011/12)
Public wholesaler total sales** 125 50% (2011)
Public wholesaler sales not Vertical Programme/directly 
donor-funded	**  37.2 15% (2011)
Tax-funded share of treasury funds to public 
wholesaler***  11.3 5% (2011/12)
Sources: *Interviews; **MSD (2013); ***MoHSW (2013, pp. 4–5).
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As Table 13 illustrates, about half of the Tanzanian medicines market consists of largely 
donor-funded	public	purchasing,	while	as	much	again	is	spent	privately,	by	patients	and	(a	
small share) by insurers. The health sector market for other supplies is also large. It follows 
that so long as these supplies are produced domestically, health care potentially generates 
further employment within the domestic economy through these industrial linkages: direct 
employment in manufacturing, and then further employment in the “upstream” suppliers 
of those items. So, for example, Table 8 showed that there were approximately 1300 
regular	employees	in	the	Tanzanian	pharmaceutical	industry	in	2013.	In	addition,	the	jobs	
of employees in the Arusha bed nets producer, A–Z, and of some of those working in 
businesses such as those producing hospital furniture, mattresses, textiles, packaging 
(card and plastic), brushes and recycled plastics, and detergents and other cleaning items, 
also partly depend on health sector demand.
The public wholesaler, MSD, is an important buyer of both medicines and other essential 
supplies. Tables 14 and 15 show two measures of the size of the public sector market. 
Table 14 shows the value of medicines and supplies distributed by MSD to health facilities, 
including	a	projection	for	2015/16.	Table	15	shows	the	breakdown	of	funding	sources:	these	
data	are	for	calendar	year,	not	fiscal	year,	and	refer	to	funded	procurement,	not	distribution,	
so	the	two	sets	of	figures	complement	each	other.	The	share	of	donor	funding	to	domestic	
funding	 fluctuates	 according	 to	 donor	 funding	 schedules.	 However,	 both	 sets	 of	 data	
suggest	considerable	fluctuations	 in	medicine	and	supplies	procurement	and	distribution	
and hence in availability at the local level.
Table 14: Value of pharmaceuticals and medical supplies distributed to
zones	and	finally	to	customers,	2012/13–2015/6	(projected)
Year Value(TZS million) Exchange rate
Value
(US$ million)
2012/2013 163,915.6 1571.62 104.3
2013/2014 234,002.8 1574.01 148.7
2014/2015 168,251.4 1725.85 97.5
2015/2016 projected 266,147.2 2148.52 123.9
Source: MSD office records. 
Notes: The value is inclusive of special orders, normal stock (catalogue), and vertical 
programmes. Exchange rates 31 December, Bank of Tanzania average buying/selling prices: 
https://www.bot-tz.org/FinancialMarkets/ExchangeRates/ShowExchangeRates.asp.
Table 15: MSD: Procurement of pharmaceuticals and supplies,
2013 and 2014 (US$ million)
Category of procurement 2013 2014
Pharmaceuticals  19.2  28.6 
Medical supplies and lab reagents  36.1  16.3 
Special procurement (pharmaceuticals and medical supplies)  12.4  7.2 
Vertical Programme (donor funded)  30.5 169.5 
Opportunistic infections (donor funded) 	-	 30.5 
Total  98.1 252.2 
Share	domestic	(non-donor)	funding	(%)  68.9%  20.7%
Source: MSD office records. Note: TZS /US$ exchange rates 30th June of relevant year, 
BoT as above. 
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The private market has also been expanding in recent years, in terms of the availability 
and variety of supplies and medicines. Our recent research sought to gain understanding 
of	 interviewees’	 impressions	of	market	 trends	 –	 specifically,	whether	 supplies	 availability	
on the market and from wholesalers had improved or declined recently, with detail. 
Interviewees in all sectors replied that availability of pharmaceuticals and other supplies in 
the Tanzanian private market had increased in recent years, as compared to some years 
back.	In	public	and	FBO	facilities,	donations	were	also	said	to	play	a	role	in	filling	the	gap	in	
supply	shortages.	The	majority	of	respondents	firmly	stated	that	pharmaceuticals	and	other	
supplies had become more readily available in recent years. However, some respondents 
explained that this liberalization of the medicines market was a threat to local pharmaceutical 
manufacturers,	and	others	said	public	facilities	were	not	benefiting	from	this	situation.	Box	
2 contains illustrative examples of what they said.
Box 2
This has also contributed to low consumption of the locally made items, and I think even some of 
the manufacturers have been kicked out of the market. (Private dispensary, District 1)
Yes.	There	are	so	many	medical	supplies	on	the	market	if	you	compare	with	what	was	there	10	
to 15 years ago. The only challenge that I see is that the availability is not controlled today, and 
so	we	have	so	many	sub-standard	or	fake	things,	including	drugs	and	equipment.	…	The	local	
manufacturers have faced competition from imported supplies, and as a result, either most of 
them have been forced out of the market, or their production has gone down because very few 
locally manufactured goods are seen in the market. (Public district hospital, District 3)
This has not brought any changes to this centre because it is a public facility and gets medical 
items	 from	 the	DMO	and	 [the	public	wholesaler].	But	 for	patients	 it	 has	had	a	positive	effect,	
because there are so many pharmacies in town and drug shops all around. If you do not wish to 
use the public dispensary medicines, you can easily get alternative medicines somewhere else. 
(Public dispensary, District 3)
These changes in medical item supply have not brought any change to this dispensary because 
it’s a government entity with a long supply chain from [the public wholesaler], but it has been a 
very good opportunity for patients. They are able to get medical items from private pharmacies 
and drug shops if they are able to [pay]. This is a good thing. (Public dispensary, District 3)
The	private	sector	was	also	experiencing	rapid	price	fluctuations.	For	medicines,	prices	in	
the private sector were found to be were generally higher than those in the public supply 
chain, as price data on median purchase prices for the tracer medicines show (see Figure 
1). MSD procurement was thus successfully reducing medicine prices for patients below 
private	market	levels.	However,	for	other	essential	supplies	this	effect	was	much	less	marked:	
a number of items could be purchased more cheaply on the private market (see Figure 2).
This section has demonstrated the economic importance and productive impacts of health 
care. It has also argued that that the full potential of these economic impacts is constrained 
by	a	number	of	factors	including	inadequate	and	fragmented	health	care	financing. More 
coherent funding, better management of human resources, well directed investment, and 
improved procurement management could pay economic dividends. The economic scale 
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and impact of health care in the Tanzanian economy is both very large, and also much less 
productive than it could be. The services could provide better health care and better health; 
health care employment could generate more domestic demand; and the procurement of 
inputs for health care could be improved, resulting in better services and more manufacturing 
employment.	Section	3	explores	the	manufacturing	impact	–	a	very	under-studied	aspect	of	
health care’s productive impact – in more detail.
Figure 1: Median purchase prices for tracer medicines from public and private 
sources	(selected	medicines	identified),	log	scale
Note: the diagonal line is the 45o line: points above the line show items for which 
the private sector price exceeded the public sector price. 
Figure 2: Median purchase prices for tracer essential supplies and equipment 
from	public	and	private	sources	(selected	items	identified),	log	scale
Note: the diagonal line is the 45o line: points above the line show items for which 
the private sector price exceeded the public sector price.
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As Section 2 showed, Tanzanian health care is an import market for manufacturers of 
medicines and supplies that form part of the population’s basic needs. Table 13 showed 
that about half of the Tanzanian medicines market consists of public purchasing (by 
MSD),	predominantly	donor-funded,	while	as	much	again	is	spent	privately	by	patients	
and (a small share) by insurers. The health care market for other essential medical and 
infection-control	 supplies	 is	 also	 large.	 It	 follows	 that,	 so	 long	 as	 these	 supplies	 are	
produced domestically, health care generates manufacturing employment within the 
domestic economy: direct employment in manufacturing and then further employment in 
the “upstream” suppliers of inputs to producing those items. 
It is hard to quantify this impact because of lack of data. Table 8 showed that there 
were approximately 1300 employees in the Tanzanian pharmaceutical industry alone in 
2013.	In	addition,	the	jobs	of	employees	in,	for	example,	the	Arusha	bed	nets	producer,	
A-Z,	 and	 some	 of	 those	 working	 in	 businesses	 producing	 items	 such	 as	 hospital	
furniture, mattresses, textiles, packaging (card and plastic), brushes and recycled 
plastics, and detergents and other cleaning items, also partly depended on health 
sector	demand.	There	were	also	many	more	people	employed	on	a	casual	or	semi-
casual basis, not registered as regularly employed, whose livelihoods nevertheless 
depended on health care demand for those goods. Finally, though not studied further 
here, we should note that services such as accounting and business services also 
serve health care demand.
3.1 Declining Local Manufacturers’ Share of the Health Sector Market
To what extent is the large health care market in fact supplied by local manufacturers? 
At	present,	health	care	 relies	predominantly	on	 imported	goods.	 It	 is	difficult	 to	obtain	
precise	figures,	but	the	available	data	all	 indicate	that	manufacturers	based	in	Tanzania	
supply a low and declining share of this expanding market (Israel at al., 2014; Wangwe et 
al., 2014).
Table	16	shows	the	data	for	local	production	of	pharmaceuticals	obtained	from	the	official	
Tanzanian manufacturing survey data, plus data for imports and exports, for 2009 and 
2013.	The	final	column	is	an	estimate	of	the	total	market	for	medicines	in	Tanzania	in	each	
year, estimated as net imports plus local production:
imports + local production - exports
In Table 16 we have included the equivalent Kenyan data for comparison. The table shows 
that despite Kenya’s much larger pharmaceutical industry, Tanzania was supplying a similar 
share of its domestic market in pharmaceuticals in 2009. However, by 2013 the Kenyan 
local share of their domestic market had continued to rise, while the Tanzanian share had 
halved.
3.  LINKAGES BETWEEN HEALTH 
CARE AND MANUFACTURING
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Table 16: Tanzanian and Kenyan pharmaceutical markets, 2009 and 2013: 
imports, exports, local production (million current US$), and market share of 
local manufacturers
Country and 
year
(1)
Imports
(US$ m)
(2)
Exports
(US$ m)
(3) Local 
production
(US$ m)
Local market 
share
(%)*
Tanzania
2009 99.4 7.9 49.2 35
2013 286.1 1.7 48.7 15
Kenya
2009 298.6 67.3 99.9 30
2013 466.4 82.1 193.1 33
*Calculated as (3) / ((1) + (3) – (2)).
Sources: Tanzania: imports and exports: Comtrade database http://comtrade.un.org/data/, 
accessed 05.08.14; local production: NBS (2012, 2013). Mid-year exchange rates from 
Bank of Tanzania, https://www.bot-tz.org/, accessed 12.02.16.
Kenya: Imports, exports, and local production: KNBS (2014, 2015). Mid-year exchange 
rates from Central Bank of Kenya, https://www.centralbank.go.ke, accessed 17.02.16.
In part, this outcome results from the particularly rapid market expansion in Tanzania (see 
Figure 3). The upper line in Figure 3 is imports of both medicines and medical supplies. The 
import trend has been sharply upwards since about 2004, driven particularly by increased (if 
uneven) donor funding for medicines (especially for HIV/AIDS, tuberculosis, and combination 
anti-malarial	therapies)	and	for	some	other	essential	supplies	such	as	bed	nets.	The	lower	
line is exports by manufacturers in Tanzania to the regional market (to the DRC, Malawi, and 
elsewhere). As the graph shows, exports started to increase up to 2009 but then fell back. 
The widening gap on the graph represents net imports: the market opportunity of which 
local manufacturers have failed (or been unable) to take advantage. 
One key reason for the loss of market share is therefore the direct international procurement 
by donors of large volumes of medicines and supplies. For these supplies for “vertical 
programmes”, MSD acts as the logistics supplier, receiving, clearing, and delivering the 
supplies. The decisions by donors to procure internationally thus restrict the extent to which 
the	Tanzanian	economy	can	benefit	from	linkages	from	health	care	funding	to	manufacturing	
development. MSD also undertakes its procurement through large international tenders 
which	are	highly	price-competitive.	Finally,	the	sharp	loss	of	market	share	by	local	firms	is	
also the result of declining output for the local private market, and loss of competitiveness 
against the prices charged by wholesale importers for private market sales. 
As Table 16 conveys, the value of pharmaceutical manufacturing output has been 
approximately	 flat	 in	 current	 dollar	 terms:	 allowing	 for	 inflation,	 output	 was	 therefore	
substantially lower in real terms in 2013 than in 2009. 
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Figure 3: The expanding local health market gap (and opportunity) 
Source: Comtrade data, http://comtrade.un.org/data/, downloaded 5.8.14.
Other evidence, and also our interviews with wholesalers, facilities, and retail shops in 
2012/13,	 confirmed	 the	 same	 trend.	 Table	 17	 shows	WHO/Health	 Action	 International	
sample data on the manufacturing origin of medicines in Tanzania, collected as panel data 
from	 facilities	 and	 shops	 at	 three-year	 intervals	 from	2006.	Using	 a	 sample	 of	 essential	
medicines,	the	data	confirm	the	considerable	decline	in	the	share	of	local	manufacturers	in	
their domestic market in Tanzania; they also show that the imports have risen predominantly 
from outside East Africa, not from Kenya, the largest regional supplier. 
Table 17: Country of origin of a tracer set of essential medicines, by year,
public and faith-based facilities, and private shops: Tanzania 2006, 2009, 2012
Year Country of origin Total
Tanzania Kenya Other
2006 33 14 53 100
2009 21 13 66 100
2012 12 11 78 100
Source: WHO/HAI survey data 2006, 2009, 2012, supplied by Mary Justin Temu; 2006 
sample of facilities and medicines only, for comparability.
Finally, our own sample data from our 2012 survey show a similarly negative story. In our 
survey	of	facilities	and	shops	in	four	districts	of	Tanzania,	just	16%	of	the	tracer	medicines	
found on the shelves had been manufactured in Tanzania: 23% of the medicines in the 
public sector, 12% in FBOs and only 9% in private facilities and shops (Israel et al., 2014). 
Table	18	furthermore	confirms	that	this	decline	is	in	part	the	result	of	the	vertical	programmes	
and associated procurement decisions of donors: almost all of the artemisinin combination 
anti-malarial	medicines	(ACTs)	and	HIV/AIDS	medication	(anti-retrovirals,	ARTs)	had	been	
imported from outside East Africa. However, chronic disease medication (e.g. diabetes and 
hypertension medicines) was also largely imported; while Tanzanian manufacturers retained 
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19%, and East African suppliers all together 27%, of the “other” medicines, including basics 
such	as	paracetamol	and	anti-worm	treatments.	
Table 18: Country of origin of tracer medicines, by type of medicines
(% by type): Tanzania, 2012
Source country ACTs (ALu) ARTs Chronic disease Other
Tanzania 10 19
Kenya 12 18
India 37 90 41 46
China 8 8
HICs 55 47 7
Other 2
Total 100 100 100 100
Source: authors’ survey data. Note that numbers may not add to 100 because of rounding.
Table 19 shows a comparable breakdown of the sources of medical equipment and other 
health care supplies, by the same country categories of supplier. Just 23% overall of the 
non-medicine	tracer	items	available	were	found	to	be	made	in	Tanzania	(Israel	et	al.,	2014).	
These	supplies	were	more	difficult	 to	 trace	to	manufacturing	source	than	the	medicines,	
so	 the	 data	 are	 incomplete.	 They	 indicate,	 however,	 that	 Tanzania-based	 firms	 had	
produced almost none of the laboratory supplies, and no basic medical equipment. These 
generalizations are backed up by the qualitative interviews. Some medical supplies and the 
majority	of	other	basic	supplies	had	come	from	Tanzania	(see	Table	19).	Most	equipment	
was from high income countries (HICs) (often donated) with a share from China and India; 
laboratory supplies were similarly from HICs, along with over 40% of medical supplies. 
Table 19: Country source of medical equipment and health sector supplies,
% by category of supplies, Tanzania 2012
Source country Medical equipment
Supplies
Medical Lab Other
Tanzania 31 3 63
Kenya 5 4 13
India 7 2 4 17
China 15 20 3 3
HICs 75 41 85 3
Other 3 1 1
Total 100 100 100 100
Note that numbers may not add to 100 because of rounding.
Table 20 lists the items found to have been manufactured in Tanzania. These were mainly 
textiles, white spirit, and cleaning items. There is thus substantial scope for expanding local 
manufacturing of health care supplies other than pharmaceuticals. 
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Table 20: Non-medicine tracer items manufactured in Tanzania 
(% by country of origin)
Item name Country of manufactureTanzania Kenya Other Total
Alcohol/ spirit for wound cleaning 100 0 0 100
Bed net 100 0 0 100
Bed sheet 100 0 0 100
Detergents 64 28 8 100
Disinfectants (Hibitane, Savlon) 38 17 46 100
Emulsion oil for laboratory 6 18 76 100
Hydrogen peroxide 100 0 0 100
Mop or broom 82 0 19 100
n=109
These data demonstrate, however, the relatively low technological level of the manufacturers 
supplying the health sector in Tanzania. The more complex categories of medical equipment 
and laboratory reagents came largely from China and other countries outside East Africa. 
Kenyan	manufacturers	were,	by	contrast,	supplying	a	larger	range	of	non-pharmaceutical	
supplies, including gloves, syringes and needles, and microscope slides; Giemsa stain and 
emulsion oil for laboratories; and plasticized bed sheeting (Kariuki et al., 2015). 
Similarly, the pharmaceuticals manufacturers were supplying largely basic formulations plus 
some	amoxicillin	syrup	for	children.	Injectables	were	wholly	imported	from	Kenya	and	other	
countries,	as	were	creams	and	IV	fluids	(see	Table	21).	This	suggests	that	the	pattern	of	
imports	 is	 determined	 in	 part	 by	 the	 currently	 limited	 technical	 capabilities	 of	 Tanzania-
based	firms.
Table 21: Country source of tracer medicines by dosage form 
(% of tracers from each country category) 
Dosage form
Country of origin
TotalTanzania Kenya India China Other
Tablet/capsule 22 9 53 1 15 100
Injectable 0 1 31 43 25 100
Syrup 9 81 6 0 3 100
Cream 0 82 6 0 3 100
IV Fluids 0 3 91 0 6
n=646
3.2 Sources of Manufacturing Decline and Constraint
Given the expanding opportunities, why have manufacturers based in Tanzania been so 
relatively unsuccessful in serving their own domestic market? Our recently completed 
study	 identifies	 four	sets	of	strongly	 interrelated	factors	and	pressures:	 increasing	 import	
competition; problems in sustaining manufacturing competitiveness through upgrading and 
cost reduction; procurement practices in all sectors that create barriers to market entry 
for	local	firms;	and	domestic	policies	that	reinforce	manufacturers’	disadvantage	vis	à	vis	
overseas exporters and local importers.
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There is evidence of rising import competition in the Tanzanian medicines market. The number 
of applications for the import of medicines submitted to TFDA (21,194: 20,233 approved, 
961	rejected)	over	 the	period	2008/09	 to	2012/13	 (TFDA,	2013)	 is	a	good	 illustration	of	
the level of competition local pharmaceutical manufacturers have to cope with. In our 
interviews,	three	firms	reported	particular	problems	with	import	price	competition	in	basic	
antibiotics.	One	firm	calculated	that	some	import	prices	for	final	formulations	of	amoxicillin	
–	a	widely-used	broad	spectrum	antibiotic	–	were	below	their	import	costs	for	inputs	before	
manufacture, strongly suggesting dumping by overseas exporters. As a result, only one of 
the	firms	previously	supplying	antibiotics	to	the	local	market	was	still	supplying	substantial	
amounts	in	2013;	one	was	thinking	of	ceasing	to	produce	them;	and	the	largest	firm	had	
ceased all production of beta lactams, the group of medicines that includes amoxicillin. 
While up to 2009 the WHO data showed a high market share for local producers of amoxicillin 
capsules,	 our	 own	 (non-comparable)	 survey	 in	 2012	 found	not	 one	 amoxicillin	 tablet	 or	
capsule manufactured in Tanzania in our sample facilities and shops. This raises worries 
concerning the security of supply, since it implies increasing reliance on a small number of 
overseas suppliers able to provide large volumes at very low prices, a situation that may 
not be sustainable. When gaps in overseas supply occur, local suppliers may no longer be 
unavailable to plug those gaps. 
The narrowing of the spectrum of medicines produced in Tanzania, represented by the 
loss	of	basic	antibiotics,	has	been	reinforced	by	the	switch	from	the	previous	first	line	anti-
malarial	medication,	sulphadoxine	pyremethanine	(SP),	to	the	newer	WHO-recommended	
artemisinin combination therapy (ACTs). SP was largely produced in Tanzania, and 
very widely distributed. ACTs, which use a more complex technology to produce hard 
combination tablets, are much more expensive, and have been heavily subsidized by 
donors. The procurement has been done internationally, a donor requirement, and MSD 
provides the logistics. Local manufacturers are able to produce the formulation and can 
upgrade (expensively) to produce the combination tablets, but they are unable to meet the 
procurement requirements. This is because the procurement volumes funded by donors are 
very	large	and	the	tender	prices	are	highly	competitive.	Local	firms,	if	offered	manageable	
procurement volumes, could develop their manufacturing capabilities and lower their prices 
in the medium term, but they need market access in order to earn revenue, learn, and 
develop the capability to compete. 
More generally, the manufacturers in Tanzania face steadily rising quality hurdles. All the 
firms	interviewed	were	actively	upgrading	and	instituting	new	processes	and/or	products.	
In pharmaceuticals, regulatory standards of Good Manufacturing Practice (GMP) strongly 
shape market access and business strategy. In Tanzania the TFDA actively pressures and 
supports	 firms	 to	 upgrade	 to	 its	GMP	 standards;	 these	 are	 currently	 being	 harmonized	
at the EAC level. Furthermore, GMP standards rise with technological change over time. 
The	result	 is	financial	pressure	on	firms	to	find	sources	of	 investment	finance	to	support	
continuous	upgrading,	in	conditions	of	sharpening	price	competition	–	a	difficult	challenge	
where loan funds are expensive. 
The	same	challenge	faces	the	producers	of	other	essential	supplies.	These	firms	too	are	under	
pressure from competition. Among producers of brushes and related cleaning equipment, 
one	firm	had	fought	off	Chinese	import	competition	by	switching	to	locally	recycled	plastic,	
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requiring	new	machinery	and	upgrading	of	 local	plastic	suppliers.	A	 furniture	firm	whose	
product range included specialized hospital furniture had upgraded its powder coating and 
sandblasting	machinery.	Finally,	a	large	successful	bed-nets	supplier	was	using	Japanese	
technology	and	the	Japanese	no-fault	manufacturing	processes	to	try	to	fight	off	what	they	
described	as	“cut-throat”	international	competition.	
In these circumstances, procurement processes are key to market access and business 
survival. Given the large size of the public procurement market, the public sector procurement 
rules	will	strongly	 influence	manufacturing:	 in	effect,	health	sector	procurement	 is	part	of	
industrial strategy. Public procurement is undertaken by MSD, which has a near monopoly 
in organizing procurement through tendering processes, and in receiving orders and 
aggregating supplies for more than half of the health sector’s consumption. During the 
interviews for our study, local manufacturers of pharmaceuticals and other supplies said 
that they experienced tendering to supply MSD as increasingly risky. The main tendering 
risks	manufacturers	identified	were:	very	low	margins,	delayed	payment	putting	cash	flow	at	
risk, very large tender size straining production capacity, incomplete purchase of contracted 
orders	creating	losses,	delayed	notification	of	delivery	dates	creating	unmanageable	 lead	
times, high tendering costs with low probability of success, lack of trade credit increasing 
working	 capital	 financing	 costs,	 and	 short	 (one-	 or	 two-year)	 contracts	 that	 provided	
insufficient	 market	 access	 guarantees	 to	 support	 financing	 of	 required	 investment	 and	
acquisition of the requisite technology. Not all these factors were under MSD’s control. For 
example, Ministry of Finance delays in funding have undermined MSD’s performance and 
that of the broader health sector (MSD, 2013).
Our survey data suggest, however, that, despite these problems, public sector procurement 
is still more likely to source medicines locally than are private buyers. Our data show that 
procurement and wholesaling for the health sector in Tanzania is quite segmented: most 
medicines and supplies in public facilities are from the public wholesaler (MSD) while almost 
all supplies and medicines in private facilities and shops were bought privately; only the FBO 
sector had mixed suppliers. Tables 22 and 23 show procurement patterns by country and 
by wholesale sector. For medicines (see Table 22), similar percentages came from outside 
East Africa, but the private wholesalers showed a relative preference for Kenyan suppliers. 
Many private wholesaler/importers represent large exporters from India and Kenya. For 
supplies	 the	 pattern	was	 reversed	 (Table	 23),	 reflecting	 the	 sourcing	 of	 basics	 such	 as	
cleaning items in local shops, as well as locally manufactured textile products.
Table 22: Country of origin of tracer medicines, by wholesale source sector
(% of all tracers)
Country of origin
Sector where sourced (wholesale)
Total
Public Donation Private
Tanzania 22 0 11 16
Kenya 10 25 20 15
Other 68 75 69 68
Total 100 100 100 100
n=609
Note: totals may not add to 100 because of rounding.
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Table 23: Country of origin of other tracer commodities, by source of items 
(wholesale sector) (% of all tracers by sector)
Country of origin
Type of source
Total
Public sector Donation Private wholesaler
Tanzania 18 2 33 23
Kenya 5 2 5 5
Other 77 96 62 73
Total 100 100 100 100
n=453
Our	 interviews	 also	 identified	 tax	 and	 tariff	 structures	 that	 tended	 to	 disadvantage	 and	
discourage	local	producers.	Medicines	and	medical	supplies	enter	the	country	at	zero	tariff	
rates and are zero rated for VAT. In principle, according to the Tanzania Revenue Authority 
(TRA),	a	 “level	playing	field”	with	 importers	has	been	created	 for	 local	manufacturers	by	
also exempting inputs for local production of the same items. In practice, manufacturers 
and the TRA agreed that it is too complicated to achieve this outcome. The main reason 
lies in the complexity of identifying the relevant inputs beyond items such as bulk active 
pharmaceutical ingredients (APIs). The manufacturers interviewed documented in detail 
the	tax	and	tariff	disadvantages	they	effectively	suffer	relative	to	importers.	Explaining	the	
disincentive	 nature	 of	 the	 tariff	 system	 to	 local	 producers,	 a	 respondent	with	 long-term	
experience with pharmaceutical issues in the health system said: “at present when you 
import medicines you do not pay taxes. So why should a businessman import raw materials 
that are taxed so as to produce pharmaceuticals locally?” This is a key reason why local 
firms	were	moving	out	of	basic	affordable	medicines	and	other	supplies,	because	they	were	
no	longer	profitable.	
In	 terms	 of	 industrial	 support,	 the	 interviews	 identified	 serious	 gaps	 in	 accessing	
technological information and support as well as access to support to build the marketing 
and	 commercial	 capabilities	 in	 smaller	 firms.	 Some	 respondents	 in	 health	 facilities	 and	
pharmacies	complained	about	the	poor	quality	of	some	of	locally-produced	medicines,	citing	
low technological capability as a contributory factor. The manufacturers also experienced 
a shortage of workers with appropriate skills. Pharmaceuticals are a higher skill area and 
constant	upgrading	requires	matching	skills,	but	pharmaceutical	firms	were	facing	shortages	
of	skilled	staff	such	as	industrial	pharmacists	and	pharmaceutical	technicians.	Furthermore,	
firms	 reported	 high	 turnover	 of	 skilled	 staff	 and	 complained	of	 the	difficulty	 and	 cost	 of	
obtaining work permits for experts from outside the country. 
Finally,	there	are	the	well-known	problems	of	power	and	infrastructure	constraints:	production	
in the pharmaceutical sector, as in the whole industrial sector, faces high power prices and 
unpredictable power outages that damage machinery, as well as having to use water that 
requires	expensive	purification.	
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Section	3	has	documented	a	major	human	development	opportunity	that	is	being	largely	
missed in Tanzania. Meanwhile other countries, such as Ethiopia and Ghana, are seizing 
this opportunity. Health care, as Section 2 showed, generates large social and economic 
benefits	through	its	contribution	to	domestic	demand,	employment,	industrial	growth,	and,	
not	 least,	 improved	health.	However,	 the	economic	benefits	of	health	care	 for	Tanzanian	
development could be greatly increased by paying closer attention to the impact of health 
policy on industrial development, and in turn, industrial development could help to break the 
health care supplies constraints documented in Section 2, improving health care as a result. 
Health policies concerning the funding and procurement of medicines necessarily constitute 
an	 industrial	policy	–	 they	 influence	 industrial	development.	The	question	 is	whether	 that	
industrial impact is positive or negative, and how to institute and sustain a virtuous circle of 
mutual	benefit	between	industrial	and	health	policy	to	support	human	development.	
The	potential	benefits	of	sourcing	more	medicines	and	other	essential	supplies	locally	are	
immense, not only for local manufacturers but for the growth of the economy as a whole. 
They	include	increased	employment	in	one	of	Tanzania’s	higher-skill	sectors,	reducing	the	
trade	deficit,	and	reinforcing	development	synergies	between	health	needs,	health	financing,	
and industrial growth (Wangwe et al., 2014). 
Strikingly, other African countries are seizing this opportunity. Ethiopia is a leading example. 
Ethiopian health and national drug policies recognize the development of local capability in 
manufacturing pharmaceuticals and other medical supplies as key to increasingly assuring 
the	availability	of	those	items,	including	associated	skills	and	scientific	capability	development.	
The country has generated rapid growth in the local production of pharmaceuticals and 
medical	supplies	manufacturing	since	2007,	based	notably	in	industrial	joint	ventures;	the	
country now has 13 pharmaceutical manufacturers, nine producing medicines including 
antibiotics and large volume parenterals, one manufacturing empty gelatine capsules, 
and the rest producing medical supplies such as syringes, absorbent cottons, gauzes, 
bandages,	and	sanitary	products	(Gebre-Mariam	et	al.,	2016).	
Ghana has also created policies to strengthen its pharmaceutical manufacturing capabilities. 
It	has	banned	 the	 imports	of	 finished	 formulations	of	14	widely	used	products	 including	
ampicillin, tetracycline, chlordiazepoxide, indomethacin, paracetamol, aspirin, and 
diazepam.	Ghana	also	offers	selective	industrial	protection	to	pharmaceuticals	by	combining	
zero import duties on their materials and machinery requirements with 10% import duty on 
finished	formulations	(Chaudhuri,	2016).	
This section outlines a policy framework to create a more positive interaction between 
health and industrial policy, based on our recent research and the experience of competing 
countries such as Ghana and Ethiopia. Our interviews with Tanzanian health facility and 
shop personnel responsible for procurement showed substantial support for policies to 
encourage more local manufacturing for the health sector. Box 3 gives some representative 
4.  INTEGRATING HEALTH AND 
INDUSTRIAL POLICY
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examples of their views. A number of health sector respondents in all sectors felt there was a 
need to increase the local production and supply of pharmaceuticals and essential supplies. 
Potential	benefits	that	were	mentioned	included	lower	prices,	shorter	supply	chains,	closer	
regulatory supervision, and hence improved speed of delivery and better quality. 
Box 3:
This [more locally manufactured supplies] is very important for the private [health] sector. 
We	are	facing	a	big	problem	and	we	cannot	afford	to	pay	high	salaries.	If	medicines	and	
supplies were cheaper, we could manage to increase salaries. Also, if supplies were 
locally produced, it would be easier to control quality. We are facing a big problem of 
financing.	Donations	are	now	very	rare,	so	having	more	local	supplies	would	help.	(Facility	
in-charge,	faith-based	health	centre,	District	3)
It is possible for the health system to source more from local manufacturers than it does 
now because the process of ordering and delivering will be much easier. For example, 
ordering	and	delivering	will	be	within	the	same	locality.	…	The	monitoring	process	would	
also be easy, since the health system will be in a position to monitor right from the primary 
stage of production, and quality of drugs would be assured right at the factory level. 
The	effect	of	damages,	delays	in	ordering	and	actual	supplying,	issues	of	transport,	and	
quality	checks	of	drugs	for	quality	after	delivery	would	all	be	avoided.	(In-charge,	public	
health centre, District 4)
If industrial and health policy can be brought closer together, locally manufactured 
supplies of pharmaceuticals and other essential health care supplies can be improved. 
Manufacturers	 can	 exploit	 the	 domestic	 market	 opportunities	 more	 effectively,	 while	
improving supplies for health care. To achieve this, elements of both industrial policy and 
health	policy	would	have	 to	change.	Participants	 in	a	high-level	consultative	workshop	
in Tanzania at the end of our study emphasized the need for a policy vision, prioritizing 
industrial	development	in	this	sector	in	order	to	deliver	interconnected	benefits	including:	
new manufacturing investment and rising employment; rising skill levels; improving 
technical	and	scientific	capability	to	address	health	needs;	fewer	stock-outs	of	essential	
supplies in health facilities; rising exports; and a health system and economy with greater 
security and the ability to cope with emergencies, and which is less reliant on the vagaries 
of import suppliers and donors.
We summarize here our recommendations for health policy changes, and for changes in 
industrial policies towards pharmaceuticals and towards other supplies. 
On	the	health	sector	side,	the	main	challenges	are	improved	domestic	financing	for	health	
sector	supplies,	allied	to	more	local-industry-friendly	procurement	rules.	The	private	sector	
wholesalers have strong institutional ties to exporters in India and Kenya, acting as their 
local sales representatives in Tanzania, and in pharmaceuticals private wholesalers are even 
less likely to buy essential medicines locally than is the public sector. A twin shift to a lower 
share	of	out-of-pocket	payment	in	health	supplies	financing	and	a	set	of	public	procurement	
policies supporting stable development of competitive local suppliers can improve the 
availability of supplies in public facilities, reduce costs to patients, and facilitate higher health 
sector	productivity	with	broad	economic	benefits.	
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Such a shift in procurement policies requires a recognition that while the high volume of 
donor funding is, as has been shown, currently very important in providing the material 
inputs for health care, the form in which aid is currently provided has had negative 
implications for local industrial development. Donors’ reliance on the external procurement of 
medicines and supplies for import has restricted the scope for backward industrial linkages 
from health care to manufacturing in the Tanzanian domestic market. Collaborative work 
between government and donors, to revise these procurement practices in order to reduce 
the barriers to market entry facing local manufacturers, can turn valued donors’ medicine 
funding into a vehicle for change to rebuild and strengthen linkages between health policy 
and industrial policy. 
In pharmaceuticals there has been a clear problem of deindustrialization. In a commissioned 
report to COSTECH on promoting local pharmaceutical production (REPOA, 2015), building 
on	the	workshop	discussion,	the	research	team	made	five	sets	of	policy	recommendations,	
as follows.
First,	 we	 recommended	 that	 the	 government	 prioritize	 support	 for	 the	 industrial	 firms	
producing pharmaceuticals and medical supplies as a strategy for realizing a vibrant 
health sector. In order to ensure coordination the government should put in place a lead or 
champion in the form of an organization or unit that can take the lead within government.
Second, we proposed that the government should support the development of the 
pharmaceutical industrial base by adopting a selective import protection policy for the 
pharmaceuticals industry. This is needed, we argued, because the industry requires 
sustained	market	access,	and	cash	flow,	in	order	to	facilitate	the	building	up	of	larger	scale	
and higher technical capabilities to serve the expanding national and regional markets.
Third,	building	on	the	findings	summarized	in	Section	3,	we	argued	that	the	approach	to	
public sector procurement should be reviewed with a view to making public procurement an 
instrument for supporting local manufacturing and a positive element of domestic business 
development. 
Fourth, in addition to selective import protection, we argued that support – technical and 
financial	 –	 should	 be	 provided	 to	 the	 pharmaceutical	 industry	 to	 enable	 it	 to	 engage	 in	
continuous technological upgrading, technological learning, and access to technological 
information with a view to facilitating the industry to move up the technology ladder. 
Finally, but central to the chances of success, we argued that government intervention 
to facilitate access to the requisite skills for the pharmaceutical industry should address 
the	 current	 skill	 gaps	 through	 innovative	 public-private	 sector	 collaborations	 and	 the	
subsidization of training in scarce skills for the industry.
Many	 of	 these	 industrial	 policy	 recommendations	 apply	 also	 to	 the	 non-pharmaceutical	
supplies sector. As outlined, that sector also faces a challenge of industrial upgrading to 
meet external competition, and to move into new and more technically advanced products. 
A number of our supply chain interviewees noted a recurrent problem in the supply of 
clinical gloves, and argued that it was strange that Tanzania could not produce gloves. One 
interviewee	discussed	the	possibility	of	assembling	diagnostic	kits	in	Tanzania.	A	plastics	firm	
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commented that they could produce plastic bottles for syrups – replacing imported glass 
–	if	they	had	a	long	enough	supply	contract	to	justify	the	investment.	Shifting	the	tax	and	
trade rules to favour local production over importing, and providing trade credit, technical 
support, and skills training, could support a shift towards more industrial employment in the 
non-pharmaceutical	health	supplies	industries.
The importance of rebuilding the pharmaceutical industry in Tanzania has now been clearly 
recognized	in	government	policy.	Tanzania’s	second	Five	Year	Development	Plan	(URT,	2016)	
entitled “Nurturing Industrialization for Economic Transformation and Human Development” 
identifies	 pharmaceuticals	 as	 a	 priority	 sector.	 One	 of	 the	 three	 key	 interventions	 in	
manufacturing is stated as: 
Developing productive capacities in the following industries: petro and chemicals, 
pharmaceutical,	building	and	construction,	agro	and	agro-processing	(cotton	to	clothing,	
textiles and garments, leather) coal, iron and steel. (p.48)
This recognition of the importance of pharmaceutical development forms one of the 
building blocks required for establishing much greater policy coherence between health 
and	industrial	policies.	On	the	health	side,	the	first	strategy	on	medicines	and	supplies	in	
the Tanzanian Health Sector Strategic Plan III 2009–2015 was to “ensure accessibility at all 
levels	of	safe,	efficacious	pharmaceuticals,	medical	supplies	and	equipment”.	Health	policy	
documents can now clearly state that one way of ensuring constant and adequate availability 
of	pharmaceuticals	and	other	medical	supplies	 is	to	encourage	 local	production.	Health-
industry	collaboration	to	increase	the	developmental	benefits	from	the	health	sector	requires	
institutional changes and rethinking in both health and industrial policy and implementation 
– changes that are now underway (Mackintosh et al., 2016b). Each sector needs to build 
collaborative	capabilities	–	that	is,	the	capability	to	respond	effectively	to	the	opportunities	
offered	by	the	other	sector,	and	to	create	incentives	for	extracting	mutual	benefit.	
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Strengthening	synergies	between	health	policy	and	industrial	policy	can	yield	mutual	benefits	
between health care and industrial development to support human development. We have 
argued	that	Tanzania	has	been	missing	out	on	a	major	opportunity	for	promoting	human	
development,	by	failing	to	exploit	the	domestic	market	benefits	of	health	care.	By	improving	
and	integrating	the	local	financing	of	health	care	(public	financing	and	social	insurance);	by	
integrating training and employment with health care infrastructure investment; by working 
with donors to ensure that valuable external funding for medicine and supplies supports 
Tanzanian industrial development, and by instituting an active industrial policy to support 
industrial suppliers of medicines and other essential health care supplies before the industrial 
capabilities are lost, Tanzanian policy makers can multiply dramatically the impact of health 
care on Tanzanian industrial development. 
The policy challenge is to change the ways of working to achieve policy collaboration and 
integration,	which	 requires	changing	 the	mind-set	of	 viewing	health	policy	and	 industrial	
policy as separate and mutually exclusive spheres, instead recognizing and building on 
the	 synergies	 between	 them.	 We	 have	 documented	 the	 fragmentation	 of	 financing	 in	
health care, creating “silos” of independent decision making on, for example, procurement 
strategies and industrial policy priorities. However, there is now a clear emerging recognition 
in Tanzania that more collaboration among policy makers towards shared goals of industrial 
and health care development is desirable. We hope that this paper contributes to identifying 
a	route	to	better	health-industrial	integration	for	human	development.	
5.  CONCLUSION: HEALTH AND 
INDUSTRIAL POLICY FOR HUMAN 
DEVELOPMENT
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Appendix Table A1: Tracer medicines list, Tanzania
ARTEMETHER + LUMEFANTRINE (AL/ALU: adult); 120+20mg
SULFADOXINE	+	PYRIMETHAMINE	(SP);	500+25mg
QUININE; 600mg/2ml
AMOXICILLIN (adult); 250mg/500mg
AMOXICILLIN	SYRUP	(child);	125mg/5ml
BENZL PENICILLIN; 5000000IU (5MU)
CIPROFLOXACIN; 250/mg500mg
ATENOLOL; 50mg/100mg
PARACETAMOL; 500mg
DICLOFENAC; 50mg/100mg
ZIDOVIDINE/LAMIVUDINE/EFAVIRENZ (AZT+3TC+EFV); 300mg+150mg+6000mg
ZIDOVIDINE/LAMIVUDINE/NIVERAPINE (AZT+3TC+NVP); 399mg+150mg+200mg
TENOFOVIR/ENTRICITABINE/Lpv/r; 200mg+200mg+200/50mg
OXYTOCIN;	10iu	&	5iu	per	ml
METRONIDAZOLE; 200mg/400mg
FLUCONAZOLE; 50mg/150mg/200mg
MEBENDAZOLE; 100mg
OMEPRAZOLE; 20mg
CLOTRIMAZOLE cream; 1%
AMITRIPTYLLINE;	25mg
METFORMIN; 500mg
GLIBENCLAMIDE; 5mg
LOPERAMIDE	HYDROCHLORIDE;	2mg
NORMAL	SALINE	AND	5%	DEXTROSE	(IV	fluid)
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Appendix Table A2: List of other tracer supplies, Tanzania
EQUIPMENT MEDICAL/OTHER SUPPLIES LABORATORY SUPPLIES
THERMOMETER SURGICAL GLOVES GIEMSA STAIN
BLOOD PRESSURE 
MACHINE GAUZE BANDAGES EMULSION OIL
MICROSCOPE CREPE BANDAGES DETERMINE HIV TEST KIT
SLIDES (FOR 
MICROSCOPE) SYRINGES	AND	NEEDLES
RAPID DIAGNOSTIC TEST FOR 
MALARIA
STETHOSCOPE HYDROGEN	PEROXIDE	(H202)
GRAME STAIN REAGENT 
FOR TESTING BACTERIAL 
INFECTION
FOETOSCOPE FOR 
MIDWIFERY
ALCOHOL/SPIRIT FOR WOUND 
CLEANING HAEMOQUE FOR HB LEVEL
GLUCOMETER DISINFECTANTS (HIBITANE OR SAVLON) SD	BIOLINE	FOR	SYPHILIS
STRIPS (FOR 
GLUCOMETER)
MACKINTOSHES/PLASTICIZED 
SHEETING
WEIGHING SCALES 
(FOR PAEDIATRICS) BED NET
CD4 MACHINE BED SHEETS
SHARPS BOX MOP OR BROOM
DETERGENTS
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(Endnotes)
1	 Source:	World	Health	Organization	data,	http://apps.who.int/gho/data/node.country.country-TZA.
2 Calculation supplied by A.R. Channon; data from Mackintosh et al. (2016b).
3  Data obtained from the Department of Policy and Planning, Ministry of Health, Community Development, Gender, 
the Elderly, and Children (MHCDGEC).
4	 	Draft	PER	estimates	for	FY	2014/15:	data	obtained	from	the	Department	of	Policy	and	Planning,	Ministry	of	Health,	
Community Development, Gender, the Elderly, and Children (MHCDGEC).
5	 	Draft	PER	estimates	for	FY	2014/15:	data	obtained	from	the	Department	of	Policy	and	Planning,	Ministry	of	Health,	
Community Development, Gender, the Elderly, and Children (MHCDGEC).
6 Note that the National Health Insurance fund does not count as public spending.
7	 	Draft	PER	estimates	for	FY	2014/15:	data	obtained	from	the	Department	of	Policy	and	Planning,	Ministry	of	Health,	
Community Development, Gender, the Elderly, and Children (MHCDGEC).
8  Data obtained from the Department of Policy and Planning, Ministry of Health, Community Development, Gender, 
the Elderly, and Children (MHCDGEC).
9 Information supplied by the Pharmacy Council of Tanzania.
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The Economic and Social Research Foundation (ESRF) is an independent policy research institution based in Dar es 
Salaam, Tanzania. ESRF was established in 1994 to respond to the growing need for a research think tank with a 
mandate to conduct research for policy analysis and capacity building. The Foundation’s primary objectives are therefore 
to undertake policy-enhancing research, strengthen capabilities in policy analysis and decision making, as well as 
articulate and improve the understanding of policy options in government, the public sector, the donor community, and 
the growing private sector, and civil society.
Vision:
Advancing knowledge to serve the public, the government, CSOs, and the private sector through sound policy research, 
capacity development initiatives, and advocating good development management practices.
Mission:
To become a national and regional centre of excellence in policy research and capacity development for policy analysis 
and development management.
Objectives:
The overall objective of ESRF is to conduct research in economic and social policy areas and development management, 
and use its research outcomes to facilitate the country’s capacity for economic development and social advancement.
“This ESRF Discussion Paper is based on the output of the Tanzania Human Development Report 2017”
